GRANT OF OPTIONS AND DIRECTORS DEALING

RNS Number : 8160V

C4X Discovery Holdings PLC

02 February 2017

 

2 February 2017

C4X Discovery Holdings plc

("C4XD" or the "Company")

GRANT OF OPTIONS AND DIRECTORS DEALING

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, announces that on 1 February 2017, 100,000 options over ordinary shares of the Company ("Ordinary Shares") were awarded pursuant to the EMI 2014 Plan to certain employees, including 50,000 options to Dr. Craig Fox, Chief Scientific Officer, as set out below.

Name	Position	Number of share options awarded	Option exercise price per share (pence)	Percentage of issued share capital (%)
Craig Fox	Chief Scientific Officer	50,000	91	0.13%

Following this award, Craig Fox holds options over 200,000 Ordinary Shares, representing 0.53% of the Company's issued share capital. The options have an exercise price of 91p, being the average of the mid-market closing price of the Ordinary Shares over the three days prior to 1 February 2017. The options can be exercised at any time between 3 years and 10 years of them being granted.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr. Craig Fox
2	Reason for the notification
a)	Position/status	Chief Scientific Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	options over 1p ordinary shares - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) N/A 50,000
d)	Aggregated information	Price(s) Volume(s) N/A 50,000
e)	Date of the transaction	1 February 2017
f)	Place of the transaction	N/A

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                             07801 865 803

Zeus Capital Limited

Dan Bate                                                                                                                              0161 831 1512

Dominic Wilson/Phil Walker                                                                                      0203 829 5000

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Melissa Gardiner                                        0203 709 5700 

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

 

END

 

 

DSHUARURBAAURUR